The Silent
Epidemic
of Our Time.
589 million adults are living with diabetes worldwide — and the number is rising faster than any health system can respond. This is the story of how diagnostic precision is rewriting the outcome.
Three moments that
define a patient's journey.
Every diabetes care pathway hinges on three diagnostic decisions. Get them right, and you change lives. Get them wrong, and the cost — human and economic — compounds for decades.
Diabetes is not a single event — it is a lifelong narrative. From the first suspicious blood sugar reading to the daily finger-prick ritual, to the quarterly HbA1c check that determines whether treatment is working, every step requires a diagnostic answer.
Our portfolio is architected around these three moments: Diagnosis — identifying patients before complications begin. Daily Monitoring — empowering self-management at the point of care. Compliance Monitoring — the 2–4 times per year when clinicians need gold-standard HbA1c data to adjust therapy.
From the compact HumaMeter A1c that fits in a primary care clinic, to the H100 Plus HPLC system that anchors a national reference laboratory, we meet every facility where it is — not where we wish it to be.
The Diabetes Atlas
Seven regions. One crisis. The burden of diabetes is not distributed equally — and neither is the access to diagnosis.
Facts that should
keep us awake.
Diabetes is a huge and growing problem. The costs to society are high — and escalating. These are the numbers every healthcare leader must know.
The most deadly NCD under 60.
Diabetes is the most deadly Non-Communicable Disease in people under 60 — stealing decades of productive life, often silently.
12% of global health expenditure.
Nearly one in every eight dollars spent on healthcare worldwide goes to diabetes — $727 billion annually and climbing.
Growth in the next 20 years.
In the next two decades, the number of diabetes patients will grow in most countries — outpacing the capacity of existing diagnostic infrastructure.
A healthcare cost burden.
Diabetes is not just a clinical challenge — it is a macroeconomic one. Every dollar spent on complications could have been spent on prevention with earlier diagnosis.
338% cost increase in 17 years.
Global diabetes health expenditure has risen from under $300B to over $1T in less than two decades — an unsustainable trajectory.
1 death every 9 seconds.
In 2024, diabetes was responsible for 3.4 million deaths. Behind each number is a family, a community, a lost future.
Meeting every lab
where it is.
From point-of-care to national reference laboratories, our portfolio is designed to meet facilities at their throughput level — not force them into a one-size model.
Beyond the price tag.
True value in diagnostics is measured in outcomes prevented, time saved, and trust earned — not in unit cost alone.
Clinical Confidence
NGSP-certified HbA1c methods. IFCC-aligned results. Every number your clinicians rely on is traceable, reproducible, and defensible.
Lifecycle Partnership
24/7 technical support, ISO calibration, preventive maintenance, and clinical education — we stay with the instrument long after installation day.
Total Cost of Clarity
Fewer repeats. Fewer misdiagnoses. Fewer complications downstream. The real cost saving happens where the spreadsheet can't see it — in patient outcomes.
Every test is a decision. Every decision is a life.
Behind every HbA1c result is a patient who will either receive the right therapy at the right time — or wait another three months while their complications deepen.
At Vamn, we don't sell analyzers. We sell the certainty that when a clinician looks at a number, they can act on it. That certainty is what transforms diabetes from a silent epidemic into a manageable condition.
This is the value of diagnostic precision. This is why we exist.